Wednesday October 16, 2019 0 comments
BOULDER -- Biodesix, Inc. announced the appointment of internationally recognized lung cancer expert James Jett, M.D., as chief medical officer.
Dr. Jett joins Steven Springmeyer, M.D. as co-CMO to support all aspects of the company’s research, development and commercialization efforts.
Jett joins Biodesix from Oncimmune Ltd., where he served as chief medical officer. His career includes work as a professor of medicine at the Mayo Medical School and the University of Pittsburgh.
Jett has also served as a consultant for the National Cancer Institute in Bethesda, and he was editor-in-chief of the Journal of Thoracic Oncology from 2006-2013. His work on academic editorial boards includes Chest, Respiratory Medicine, and the American Journal of Respiratory and Critical Care Medicine.
In addition to all aspects of the company, Jett and Springmeyer will combine expertise to focus on advancing the Biodesix lung cancer and nodule management programs.
Springmeyer joined the company from Integrated Diagnostics (acquired by Biodesix in 2018) and Jett from Oncimmune (notice of acquisition in 2019).
“Biodesix is a natural continuation of my gratifying career as a physician,” said Jett.
“I believe that the future of patient care in oncology and pulmonology should be designed and innovated with the patient experience as the highest priority.
“I see Biodesix as a company leading the way in developing diagnostic tools that can help guide physicians and their patients to the most appropriate individual course of action.”
“We continue to build a portfolio of best-in class lung nodule diagnostic tests along with a team of world class clinical experts,” said Scott Hutton, Biodesix chief operating officer.
“We take lung cancer personally and by attracting the brightest minds in solving these complex diagnostic challenges we will continue to have a positive impact on physicians and their patients.”